<DOC>
	<DOCNO>NCT01548651</DOCNO>
	<brief_summary>The purpose study examine effect saxagliptin , anti-diabetes medication , hepatic myocardial fat content monocyte inflammation patient Impaired Glucose Tolerance ( IGT ) .</brief_summary>
	<brief_title>Effect Saxagliptin Treatment Myocardial Fat Content , Monocyte Inflammation</brief_title>
	<detailed_description>Obese , insulin resistant individual excess fat liver attributable alcohol know cause liver disease , condition define nonalcoholic fatty liver disease ( NAFLD ) . The fatty liver insulin resistant . Individuals fatty liver likely excess intra-abdominal fat well reduction circulate plasma adiponectin level . A new class antidiabetes medication know dipeptidyl peptidase 4 ( DPP-4 ) inhibitor ( sitagliptin , saxagliptin ) enhance circulate half life Glucagon-like peptide-1 ( GLP-1 ) , incretin hormone enhances insulin secretion/ lower glucose level , approve treat type 2 diabetes . More recently , show dipeptidyl peptidase 4 inhibitor also decrease liver fat inflammation animal model obesity increase circulating level GLP-1 . It show GLP-1 enhances liver fat oxidation , reduce liver fat synthesis , increase adiponectin level animal model vivo . Recent report suggest NAFLD associate increase risk cardiovascular disease independent associate cardiovascular risk factor . Furthermore type 2 diabetic subject impair glucose tolerance characterize increase hepatic myocardial fat leave ventricular ( LV ) dysfunction , particularly diastolic dysfunction . Myocardial steatosis independent predictor diastolic dysfunction type 2 diabetes mellitus well impaired glucose tolerance . However , effect saxagliptin therapy liver myocardial fat content , well LV systolic diastolic function patient impair glucose tolerance ( IGT ) type 2 diabetes previously study . Recently , demonstrate myocardial triglyceride content increase type 2 diabetic patient associate impaired leave ventricular diastolic function , independently age , body mass index ( BMI ) , heart rate , visceral fat , diastolic blood pressure . More recently , show obese normal glucose tolerant subject , obese subject IGT , type 2 diabetic subject increase myocardial fat compare lean subject . Thus , IGT type 2 diabetic subject increase myocardial steatosis defect LV function . GLP-1 show improve myocardial function cardiac output conscious chronically instrumented canine model cardiac injury heart failure . GLP-1 increase cardiac output reduce leave ventricular end diastolic pressure association reduce systemic vascular resistance , improve myocardial insulin sensitivity myocardial glucose uptake dog rapid pacing-induced dilate cardiomyopathy . However , previous study examine effect saxagliptin myocardial fat LV function IGT type 2 diabetic patient . Finally , effect saxagliptin vascular inflammation monocyte Nuclear Factor-KappaB ( NFkappaB ) remain studied . Patients Impaired Glucose Tolerance ( IGT ) / Impaired Fasting Glucose ( IFG ) insulin resistance well establish defect . Furthermore , state previously , myocardial hepatic steatosis well defect LV function well characterize obese , insulin resistant patient IGT . However , effect DPP IV inhibitor hepatic myocardial steatosis monocyte inflammation insulin resistant patient IGT previously study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Men woman diagnosis diagnosis Impaired Glucose Tolerance i.e . fast plasma glucose less equal 125 mg/dl , 2 hour post 75 gram oral glucose tolerance test ( OGTT ) plasma glucose 140199 mg/dl , glycosylated hemoglobin A1c ( HbA1c ) less 6.5 % per American Diabetes Association ( ADA ) criterion . Women childbearing potential ( WOCBP ) men must use acceptable method contraception avoid pregnancy throughout study manner risk pregnancy minimize . Patients must antidiabetes therapy treatment Impaired Glucose Tolerance ( IGT ) must fast plasma glucose concentration less equal 125 mg/dl . Type 1 Type 2 diabetes mellitus ( fast plasma glucose great 125 mg/dl ) . Patients must receive metformin , thiazolidinediones , sulfonylurea , DPP IV inhibitor , exenatide/liraglutide treatment treatment IGT time . Patients must receive follow medication : thiazide furosemide diuretic , betablockers , chronic medication hormone replacement therapy know adverse effect glucose tolerance level . Patients take systemic glucocorticoid also exclude . Subjects history clinically significant heart disease , peripheral vascular disease , pulmonary disease . Subjects must Body Mass Index 3035 kg/m2 stable body weight . Subjects must clinically significant liver disease ( aspartate aminotransferase ( AST ) &lt; 2.5 time upper limit normal , Alanine transaminase ( ALT ) &lt; 2.5 time upper limit normal , Alkaline phosphatase &lt; 2.5 time upper limit normal ) , kidney disease ( Serum creatinine &lt; 1.5 mg/dl men 1.4 mg/dl woman ) significant anemia ( Hematocrit &lt; 34 vol % ) . Subjects history serious hypersensitivity reaction saxagliptin dipeptidyl peptidase 4 ( DPPIV ) inhibitor . Concomitant treatment systemic cytochrome P450 3A4 inducer . Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>